Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Golden Throat Holdings Group Co Ltd ( (HK:6896) ) just unveiled an update.
Golden Throat Holdings Group Company Limited has updated the terms of reference for its Board Nomination Committee, originally adopted in 2015 and now revised as of 24 December 2025. The revised framework formalises the committee’s composition, requiring at least three directors with a majority of independent non-executive directors, mandates at least one director of a different gender, and sets out rules on appointment of the committee chairman and secretary, tenure aligned with the company’s articles, and meeting quorum. These governance changes aim to strengthen the company’s board nomination process, enhance diversity and independence in board appointments, and align with Hong Kong listing requirements, potentially improving oversight and confidence among investors and other stakeholders.
The most recent analyst rating on (HK:6896) stock is a Buy with a HK$4.00 price target. To see the full list of analyst forecasts on Golden Throat Holdings Group Co Ltd stock, see the HK:6896 Stock Forecast page.
More about Golden Throat Holdings Group Co Ltd
Golden Throat Holdings Group Company Limited is a Hong Kong-listed company best known for its Golden Throat lozenges and related throat-care products, operating in the consumer healthcare and pharmaceutical sector with a focus on over-the-counter remedies and the Chinese market.
Average Trading Volume: 783,225
Technical Sentiment Signal: Hold
Current Market Cap: HK$2.31B
For detailed information about 6896 stock, go to TipRanks’ Stock Analysis page.